Lantheus Holdings, Inc.

NASDAQ (USD): Lantheus Holdings, Inc. (LNTH)

Last Price

115.74

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Overview

Market Cap

8 Billion

Shares Outstanding

69 Million

Avg Volume

1,074,698

Avg Price (50 Days)

84.45

Avg Price (200 Days)

68.70

PE Ratio

17.67

EPS

6.55

Earnings Announcement

01-Aug-2024

Previous Close

121.61

Open

122.40

Day's Range

114.25 - 122.83

Year Range

50.2 - 126.89

Trading Volume

1,542,408

Price Change Highlight

1 Day Change

-4.83%

5 Day Change

-6.37%

1 Month Change

42.05%

3 Month Change

81.38%

6 Month Change

118.05%

Ytd Change

83.42%

1 Year Change

29.74%

3 Year Change

354.06%

5 Year Change

309.55%

10 Year Change

1609.60%

Max Change

1609.60%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Drug Manufacturers—Specialty & Generic

Description:

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment